


Myelofibrosis Pathophysiology

MF, a rare, fatal BM cancer, is a progressive, Philadelphia chromosome–negative MPN with significant heterogeneity in natural history, mortality, and morbidity. Constitutive activation of the JAK-STAT signaling pathway is a key component in the pathogenesis and clinical manifestations of the disease, regardless of genotype, including *JAK2* mutational status.¹⁻⁴

Drivers of Disease in MF: Aberrant JAK1, JAK2, and ACVR1 Signaling¹⁻⁸


- Dysregulated JAK-STAT signaling in MF drives the production of inflammatory cytokines and clonal proliferation, leading to bone marrow fibrosis, extramedullary hematopoiesis, burdensome splenomegaly, and constitutional symptoms.¹⁻⁴
- Chronic inflammation also drives hyperactivation of ACVR1, elevated hepcidin, dysregulated iron metabolism, and anemia of MF.⁵⁻⁸

Dysregulated JAK-STAT signaling in MF¹⁻⁸



Drivers of Anemia in MF⁷

- Anemia in MF is multi-factorial and includes BM fibrosis, anemia of chronic inflammation, splenic sequestration of red blood cells, myelosuppression by some currently available JAK inhibitors, and other factors.




Adapted by GSK from Naymagon L, et al. 2017,⁷ licensed under [Creative Commons license](#)

Inflammation, Hepcidin, and Anemia in MF⁵⁻⁸

- Anemia of chronic inflammation, a contributor to anemia of MF, is a dynamic and complex process characterized by dysregulated ACVR1 signaling, increased hepcidin levels, decreased serum iron, and an iron-restricted anemia.
- Elevated hepcidin, the master iron regulatory hormone, reduces iron uptake from the gut, increases iron sequestration in monocytes and macrophages, reduces iron availability for erythropoiesis, and shortens the erythrocyte lifespan.
- Aberrant cytokine signaling in MF increases the synthesis of hepcidin:
 - Hyperactivation of ACVR1 increases SMAD1/5/8-dependent transcription of hepcidin, upregulating hepcidin production in chronic inflammation.

Dysregulated ACVR1 Signaling in MF⁵⁻⁸



Adapted from Verstovsek S, et al. *Future Oncol.* 2021;17(12):1449-1458. Copyright © 2021 Future Medicine Ltd.

This information is scientific and non-promotional in nature and is not intended for further distribution.

Abbreviations:

ACVR1 = activin A receptor type 1; BM = bone marrow; BMP = bone morphogenetic protein; EPOR = erythropoietin receptor; JAK = Janus kinase; JAK-STAT = Janus kinase-signal transducer and activator of transcription; MF = myelofibrosis; MI = medical information; MPL = myeloproliferative leukemia protein; MPN = myeloproliferative neoplasm; P = phosphorylation; RBC = red blood cell; SMAD1/5/8 = small mothers against decapentaplegic homolog 1/5/8; STAT = signal transducer and activator of transcription.

References:

- Garmezzy B, et al. *Blood Rev.* 2021;45:100691;
- Masselli E, et al. *Cells.* 2020;9(9):2136;
- Rampal R, et al. *Blood.* 2014;123(22):e123-e133;
- Guijarro-Hernández A, et al. *Cancers (Basel).* 2021;13(5):984;
- Pardanani A, et al. *Am J Hematol.* 2013;88(4):312-316;
- Ganz T. *N Engl J Med.* 2019;381(12):1148-1157;
- Naymagon L, Mascarenhas J. *Hemasphere.* 2017;1(1):e1;
- Chifotides HT, et al. *J Hematol Oncol.* 2022;15(1):7.